Based on this, we decided to investigate the therapeutic efficacy of these HER3-targeting affibody constructs in vivo using a preclinical pancreatic cancer model, together with the therapeutic HER3-targeting monoclonal antibody MM-121 as a comparator. Here, ERBB3 is linked to familial pancreatic carcinoma.